Unión Europea - español - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agentes antineoplásicos - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Uruguay - español - Ministerio de Salud (Dirección Oficina Central)

adium pharma (distribuido por adium uruguay s.a. en la rou fuera de zona franca) - cápsula - zanubrutinib 80 mg cápsula

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

farmaceutica continental e.i.r.l. - droguerÍa - capsula - por carpula - - zanubrutinib

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

beigene switzerland gmbh suiza - zanubrutinib 80 mg - capsulas - cada cápsula contiene zanubrutinib 80 mg